What an amazing day for the 10th Annual @MDAndersonNews Boot Walk! “Who ya gonna call? Patients Access!” Team Walkbusters! #endcancer
English
Ashley Alexander
1.1K posts
Ashley Alexander
@AshAlexander44
The University of Texas MD Anderson Cancer Center Senior Physician Liaison. Tweets are my own
Houston, TX Katılım Nisan 2015
2.3K Takip Edilen809 Takipçiler
Ashley Alexander retweetledi
“It was among the easier questions I’ve ever been asked as a cancer doctor,” says our Dr. Van Morris of being asked to walk Sheri Shaw James down the aisle. @VanMorrisMD @DrEmmaHolliday #ColorectalCancer #EndCancer
World News Tonight@ABCWorldNews
Sheri James was diagnosed with cancer, and Bill James was there to support her as she went through treatment. After she beat cancer, Bill asked her to marry him. @DavidMuir shares how Sheri asked her oncologists to be there for her wedding. #AmericaStrong. trib.al/R5L2FI4
English
Ashley Alexander retweetledi
Join me as I present “New HER2 Classification Impact to the Management of Low HER2 Metastatic Breast Cancer” at the @MDAndersonNews Physician Advisory Council!
Virtual Meeting Today at 5:30 – 6:30 p.m. CST.
Register here: mdacc.zoom.us/meeting/regist…
Houston, TX 🇺🇸 English
Ashley Alexander retweetledi
Great @UTHealthSASurg San Antonio Liver Cancer Symposium 👏 Kudos to @DrSukeshiArora Dr Cigarroa and @UnivTransplant for the excellent program 💯 @hernandezliver @MDAndersonNews #oncsurgery
English
It’s a great day to be at #SOHO22 and representing @MDAndersonNews! Make sure to stop by our booth in the exhibitor hall. #Endcancer #SOHO2022
English
Ashley Alexander retweetledi
Happening now at #ASCO22: Meet Nobel Laureate Dr. James Allison and Dr. Padmanee Sharma at booth 6122. @JimAllisonPhD @PamSharmaMDPhD #EndCancer
English
Ashley Alexander retweetledi
MD Anderson is committed to being a world-leader in cancer care, research, prevention and education. Our Strategy lays the framework for our future.
Hear from MD Anderson President Dr. Peter WT Pisters today from 11 a.m. to 1 p.m. at booth 6122. @PPisters #ASCO22 #EndCancer
English
I may be bias but we have some of the most amazing faculty!!! Those smiles light up the future of #cancer care!
Vivek Subbiah, MD@VivekSubbiah
⭐️ All the cancer breakthroughs of the last 5 years in one picture 🎯Do we go to the moon ? Mars ? No we plan to go to another galaxy to #endcancer ! Anything is possible working together with these amazing teammates @MDAndersonNews @AACR #AACR22 #precisionmedicine #immunotherapy
English
Ashley Alexander retweetledi
Dr. Amir Jazaeri serves as a discussant of the results a Phase II trial investigating durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer in a clinical trials plenary session at #AACR22. @AmirJazaeri #EndCancer
English
Ashley Alexander retweetledi
From AACR: Our Dr. Tina Cascone shares results from
the Phase II NeoCOAST clinical trial, which found immunotherapy plus durvalumab outperforms
durvalumab alone in the neoadjuvant setting for early-stage non-small-cell lung cancer: mdanderson.org/newsroom/aacr-…
#AACR22 #EndCancer
English
A wonderful inspirational article on one of my beloved colleagues @S_Champagne1960.
Multiple myeloma survivor and employee: ‘MD Anderson really is the best’ mdanderson.org/cancerwise/mul…
English
Health care providers, join us tonight’s Physician Advisory Council meeting, where we will be joined by MD Anderson President Dr. Peter WT Pisters. The virtual event is from 6-7 p.m. CST. Register here: bit.ly/3I2lfLi @PPisters #EndCancer
English
Ashley Alexander retweetledi
“This study shows axi-cel to be effective and suggests patients may receive durable benefit from receiving the treatment before being exposed to other therapies,” says our Dr. Sattva Neelapu of the ZUMA-12 findings: bit.ly/3DNJTMK #ASH21 #CART #EndCancer
English
Ashley Alexander retweetledi
HMA plus venetoclax resulted in higher response rates and longer survival than chemotherapy for patients with treated secondary AML, according to data presented by our Dr. Sangeetha Venugopal at #ASH21 (abstract 794): bit.ly/3s2Vqpi @drsangeetmd #EndCancer
English
Ashley Alexander retweetledi
What does #ASH21 mean for patients?
Watch to hear our Dr. Naveen Pemmaraju share the significance of the meeting and how it ultimately leads to better patient care. @doctorpemm #EndCancer
English
Ashley Alexander retweetledi
Want learn more 👉 Join us tomorrow (12/13), AML session #613 (4:30-6:00pm), discussing our frontline triplet (HMA+VEN+FLT3i) experience in older/unfit FLT3 mutated AML - a pooled analysis @Daver_Leukemia @TapKadia @NicholasShortMD @doctorpemm @DrHKantarjian @MDAndersonNews
Caner Saygin, MD@CanerSaygin
@musayilmaz54 is presenting dec+ven+quizartinib data in R/R FLT3-ITD #AML pts. 50% prior HMA and 80% prior FLT3i exposure. Responses are encouraging; RAS/MAPK pathway mutations emerged/persisted as possible resistance mechanism. #ASH21
English
Ashley Alexander retweetledi
Watch to hear Dr. Christopher Flowers share key takeaways from MD Anderson’s clinical trials being presented at #ASH21.
View the data: bit.ly/3E0UrIR @ChrisRFlowersMD #EndCancer
English
Ashley Alexander retweetledi
“These treatments available to us today, hopefully will become standard of care years down the road,” says our Dr. Elias Jabbour of clinical trials for leukemia. #ASH21 #EndCancer
English
Ashley Alexander retweetledi
In poster session 632 at #ASH21, he’ll discuss dose modification dynamics of ponatinib in patients with chronic myeloid leukemia (abstract 2550): bit.ly/30f4pbE #EndCancer
English
Ashley Alexander retweetledi
Meet our Dr. William Wierda by visiting booth 1212 today from 3-4 p.m. ET.
Discuss the latest in CLL, including results from the CAPTIVATE clinical trial that examined first-line treatment with ibrutinib plus venetoclax. @wwierda #ASH21 #EndCancer
English